Chemical marker of heart muscle death accurately predicts future heart attack risk

November 14, 2001

ANAHEIM, Calif. - Patients who test positive for the presence of a specific biochemical marker of heart cell death in their blood but who do not exhibit other risk factors for future heart attack should be treated as higher risk patients, according to a new analysis by cardiologists at Duke University Medical Center.

The researchers found that troponin, a protein that is released into the bloodstream as heart muscle cells die, can be a reliable indicator of future risk even when other traditional measures of heart health are negative. This is important, the researchers say, in light of the recent recasting of the definition of heart attack by the major cardiology organizations to place more emphasis on the results of troponin testing, in addition to the presence of chest pain and electrocardiogram abnormalities.

When a patient comes to the emergency room as a possible heart attack victim, physicians typically measure the heart's electrical activity (EKG) and also look for chemicals in the blood that might indicate if heart muscle is damaged or dead. For years, they have measured the levels of creatine kinase-MB (CK-MB) and, more recently, they also have been testing for troponin. Because the test for troponin can detect even small amounts of heart muscle damage, patients previously testing positive for troponin but negative for CK-MB were not always treated as being at high-risk.

"Our analysis shows that patients who test positive for troponin but not for CK-MB should still be treated as if they tested positive for both," said Duke cardiology fellow Dr. Sunil Rao. "This is important because in the past, these patients would usually not be treated aggressively."

Rao prepared the results of his study for presentation during the 74th annual scientific sessions of the American Heart Association. Both troponin and CK-MB are proteins within cells that spill out into the bloodstream as the cell wall breaks apart during cell death. The difference between the two is that troponin is only released by heart muscle, while CK-MB can be released by both dying heart and skeletal muscle.

"We believe that even low levels of troponin in the bloodstream indicate the presence of tiny heart attacks, or infarctlets," Rao explained. "The question is, does the death of a few heart cells matter, and can they be a reliable predictor of larger infarctions, or heart attacks, in the future?"

According to the Duke analysis, it does matter.

Rao and colleagues scoured the data collected from three different multi-center trials to measure the prognostic value of elevated and isolated troponin levels. Two of trials - PARAGON-B and GUSTO IIa - followed high-risk heart attack patients, and the other, CHECKMATE, looked at low-risk patients.

Patients were divided into three groups - those who were positive for both troponin and CK-MB, those who were positive for only troponin, and those positive only for CK-MB. The team found the incidence of death or heart attack after 30 days was the same for patients who only tested positive on the troponin test as for those who tested positive on both.

The researchers feel that the troponin test, which is an extremely specific and sensitive indicator of cardiac cell damage, can help physicians detect those patients who would be described as low-risk, but who actually are at a higher-risk of future cardiac events. They would even argue that troponin levels should be used instead of CK-MB in the definition of heart attack.

"For patients who come in with chest pain, EKG abnormalities and elevated markers, it is a straightforward decision to admit them to cardiac care units and begin treatment," said Duke cardiologist Dr. Kristin Newby, senior member of the research team. "However, there are many patients who may have some chest pain and unremarkable EKGs, so the chemical markers become an important determinant in how we treat them. Based on this analysis, for those with apparently ischemic symptoms, we should place equal emphasis on aggressively managing patients with only troponin elevation as on those with elevations of both markers.

"The risk of future cardiac events appears to be proportionate to degree of elevation of cardiac markers like troponin - so any elevation means risk," Newby said. "Any cell death, even if small, can be a powerful indicator of future bad events."
-end-
Other members of the Duke team were Vic Hasselblad, Robert Christenson, Dr. W. Brian Gibler, Dr. Christopher Granger and Dr. Magnus Ohman. The data analysis was supported by the Duke Clinical Research Institute.

Note to editors: Dr. Sunil Rao can be reached at (919) 668-8208 or by e-mail at rao00010@onyx.dcri.duke.edu. Dr. Kristin Newby can be reached at (919) 668-8805 or at newby001@mc.duke.edu.

Duke University Medical Center

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.